Medicine Recommendations

Red

Pending

Pending

Red

Pending

Pending

Red

Red

Pending

Botulinum Toxin Type A

Date Posted: 01 - Mar - 2014

BNF chapter: Central nervous system

Expand/Collapse

Detrusor overactivity - urology (NICE NG123)

NICE guideline NG123: Urinary incontinence and pelvic organ prolapse in women: management

Red

Red

Red

Red

Red

Red

Red

Red

Red

Botulinum Toxin Type A

Date Posted: 01 - May - 2013

BNF chapter: Central nervous system

Expand/Collapse

Chronic migraine (NICE TA260)

NICE TA260 - Botulinum toxin type A for the prevention of headaches in adults with chronic migraine

Red

Red

Red

Red

Red

Red

Red

Red

Red

Botulinum Toxin Type A

Date Posted: 01 - Mar - 2014

BNF chapter: Central nervous system

Expand/Collapse

Contracture of the joint in Multiple Sclerosis

Black

Black

Black

Black

Black

Black

Black

Black

Black

Botulinum Toxin Type A

Date Posted: 01 - Apr - 2018

BNF chapter: Central nervous system

Expand/Collapse

Cosmetic procedures

Red

Red

Red

Red

Red

Red

Red

Red

Red

Botulinum Toxin Type A

Date Posted: 01 - Mar - 2014

BNF chapter: Central nervous system

Expand/Collapse

Focal Spasticity in Multiple Sclerosis

Multiple sclerosis in adults: management (NICE CG186)

NICE Pathway - Spasticity in children and young people overview

Red

Red

Red

Red

Red

Red

Red

Red

Pending

Botulinum Toxin Type A

Date Posted: 01 - Mar - 2014

BNF chapter: Central nervous system

Expand/Collapse

Focal spasticity, Hand and wrist disability associated with stroke, Blepharospasm, Hemifacial spasm, Spasmodic torticollis.

Black

Pending

Black

Black

Pending

Black

Black

Black

Black

Botulinum Toxin Type A

Date Posted: 01 - Mar - 2014

BNF chapter: Central nervous system

Expand/Collapse

Hyperhidrosis due to social anxiety disorder

CG 159 - https://www.nice.org.uk/guidance/cg159

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Brivaracetam

Date Posted: 01 - Oct - 2016

BNF chapter: Central nervous system

Expand/Collapse

Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult, adolescents and children from 4 years of age with epilepsy

MHRA Drug Safety Update - Antiepileptic drugs: updated advice on switching between different manufacturers’ products

Amber 0

Pending

Amber 0

Amber 0

Pending

Amber 0

Amber 0

Amber 0

Pending

Bromocriptine

Date Posted: 01 - Oct - 2014

BNF chapter: Central nervous system

Expand/Collapse

Parkinson's disease

MHRA Drug Safety Update - Ergot-derived dopamine agonists: risk of fibrotic reactions

Palliative Use Only

Green (R)(Restricted)

Green (R)(Restricted)

Green (R)(Restricted)

Green (R)(Restricted)

Green (R)(Restricted)

Green (R)(Restricted)

Green (R)(Restricted)

Green (R)(Restricted)

Green (R)(Restricted)

Buprenorphine

Date Posted: 20 - Dec - 2024

BNF chapter: Central nervous system

Expand/Collapse

Pain.

Only for use in patients who are unable to take or tolerate oral medicine (including soluble tablets and liquids) OR where use of the low-dose buprenorphine patches may prevent administration problems for frail, elderly patients in the community.

Do not confuse the formulations of transdermal patches which are available in various strengths as 7-day, 4-day and 3-day patches; 3 day patches are not recommended to avoid confusion in dosing.

Always prescribe by brand name.

7 day transdermal patches: 5 microgram / hour, 10 microgram / hour, 15 microgram/hour, 20 microgram / hour (In primary care please prescribe as Sevodyne®, Butec® or Bunov®)

4 day transdermal patches are much stronger: 35 microgram/hour, 52.5 microgram/hour, 70 microgram/hour (In primary care please prescribe as Bupeaze®, Relevtec® or Carlosafine®)

Green (R)(Restricted)

Pending

Pending

Grey

Pending

Amber 0

Grey

Green (R)(Restricted)

Pending

Buprenorphine Patches

Date Posted: 01 - May - 2015

BNF chapter: Central nervous system

Expand/Collapse

Pain, in patients who are unable to take or tolerate oral medicine, (including soluble tablets and liquids).

Black

Pending

Black

Black

Pending

Black

Black

Black

Pending

Buspirone

Date Posted: 01 - May - 2013

BNF chapter: Central nervous system

Expand/Collapse

Anxiety (short term use)

Black

Black

Black

Black

Black

Black

Black

Black

Pending

Butobarbital

Date Posted: 01 - May - 2013

BNF chapter: Central nervous system

Expand/Collapse

Severe intractable insomnia only in patients already taking barbiturates

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Cabergoline

Date Posted: 01 - Nov - 2013

BNF chapter: Central nervous system

Expand/Collapse

Parkinson's disease

MHRA Drug Safety Update - Ergot-derived dopamine agonists: risk of fibrotic reactions

Red

Pending

Pending

Pending

Pending

Pending

Pending

Pending

Pending

Cannabidiol with clobazam

Date Posted: 14 - Jan - 2020

BNF chapter: Central nervous system

Expand/Collapse

Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (NICE TA614)

Red

Pending

Pending

Pending

Pending

Pending

Pending

Pending

Pending

Cannabidiol with clobazam

Date Posted: 14 - Jan - 2020

BNF chapter: Central nervous system

Expand/Collapse

Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (NICE TA615)

Black

Black

Black

Black

Black

Black

Black

Black

Black

Cannabis extract – Delta-9-Tetrahydrocannabinol (THC) 27mg and Cannabidiol (CBD) 25mg (Sativex®) oromucosal spray

Date Posted: 18 - Jan - 2023

BNF chapter: Central nervous system

Expand/Collapse

Refractory neuropathic pain

Red

Pending

Pending

Pending

Pending

Pending

Pending

Pending

Pending

Cannabis-Based Medicinal Products

Date Posted: 20 - Aug - 2020

BNF chapter: Central nervous system

Expand/Collapse

Cannabis-Based Products for the management of intractable paediatric epilepsy

Red

Red

Red

Red

Red

Red

Red

Red

Red

Capsaicin (Qutenza®)

Date Posted: 05 - Jul - 2024

BNF chapter: Central nervous system

Expand/Collapse

Treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for the treatment of pain

Green

Green

Green

Green

Green

Green

Green

Green

Green

Carbamazepine

Date Posted: 01 - Dec - 2015

BNF chapter: Central nervous system

Expand/Collapse

Trigeminal Neuralgia (as per LSCMMG Guidelines)

MHRA Drug Safety Update - Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions

Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
Next